loading
Recursion Pharmaceuticals Inc stock is traded at $6.03, with a volume of 19.49M. It is down -0.99% in the last 24 hours and down -0.17% over the past month. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$6.09
Open:
$6
24h Volume:
19.49M
Relative Volume:
2.17
Market Cap:
$2.36B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-4.3696
EPS:
-1.38
Net Cash Flow:
$-335.64M
1W Performance:
-13.24%
1M Performance:
-0.17%
6M Performance:
-34.10%
1Y Performance:
-36.26%
1-Day Range:
Value
$5.93
$6.20
1-Week Range:
Value
$5.93
$7.85
52-Week Range:
Value
$5.60
$15.74

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Name
Name
Recursion Pharmaceuticals Inc
Name
Phone
(385) 269-0203
Name
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Name
Employee
500
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
RXRX's Discussions on Twitter

Compare RXRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RXRX
Recursion Pharmaceuticals Inc
6.03 2.36B 64.60M -377.75M -335.64M -1.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-22-23 Initiated Morgan Stanley Equal-Weight
Mar-16-23 Initiated Needham Buy
Sep-16-22 Initiated KeyBanc Capital Markets Overweight
Apr-18-22 Downgrade BofA Securities Buy → Neutral
Mar-04-22 Downgrade SVB Leerink Outperform → Mkt Perform
Sep-21-21 Initiated Berenberg Buy
May-11-21 Initiated BofA Securities Buy
May-11-21 Initiated Goldman Neutral
May-11-21 Initiated JP Morgan Neutral
May-11-21 Initiated KeyBanc Capital Markets Overweight
May-11-21 Initiated SVB Leerink Outperform
View All

Recursion Pharmaceuticals Inc Stock (RXRX) Latest News

pulisher
Dec 20, 2024

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - The Manila Times

Dec 20, 2024
pulisher
Dec 20, 2024

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL

Dec 20, 2024
pulisher
Dec 20, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 0.7%Here's Why - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.6% HigherHere's Why - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap UpTime to Buy? - MarketBeat

Dec 19, 2024
pulisher
Dec 18, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.4%Time to Sell? - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Recursion Pharmaceuticals registers shares for Tempus Labs - Investing.com India

Dec 18, 2024
pulisher
Dec 18, 2024

Recursion Pharmaceuticals registers shares for Tempus Labs By Investing.com - Investing.com UK

Dec 18, 2024
pulisher
Dec 17, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.5%Here's What Happened - MarketBeat

Dec 17, 2024
pulisher
Dec 17, 2024

State Street Corp Raises Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.8%Here's What Happened - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace

Dec 16, 2024
pulisher
Dec 16, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat

Dec 16, 2024
pulisher
Dec 15, 2024

Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance

Dec 15, 2024
pulisher
Dec 15, 2024

Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX) - MSN

Dec 15, 2024
pulisher
Dec 13, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.4% HigherShould You Buy? - MarketBeat

Dec 13, 2024
pulisher
Dec 12, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3%What's Next? - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

Interesting RXRX Put And Call Options For January 2025 - Nasdaq

Dec 12, 2024
pulisher
Dec 12, 2024

Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials - Insider Monkey

Dec 12, 2024
pulisher
Dec 12, 2024

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform - Seeking Alpha

Dec 12, 2024
pulisher
Dec 11, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.7%Here's Why - MarketBeat

Dec 11, 2024
pulisher
Dec 11, 2024

Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers - Insider Monkey

Dec 11, 2024
pulisher
Dec 11, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Receives Buy Rating from Needham & Company LLC - MarketBeat

Dec 11, 2024
pulisher
Dec 11, 2024

10 AI News Investors Probably Missed - Insider Monkey

Dec 11, 2024
pulisher
Dec 10, 2024

(RXRX) Trading Report - Stock Traders Daily

Dec 10, 2024
pulisher
Dec 10, 2024

10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey

Dec 10, 2024
pulisher
Dec 10, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.2%Should You Sell? - MarketBeat

Dec 10, 2024
pulisher
Dec 10, 2024

Unpacking the Latest Options Trading Trends in Recursion Pharmaceuticals - Benzinga

Dec 10, 2024
pulisher
Dec 10, 2024

What's Going On With Recursion Pharmaceuticals Stock?Recursion Pharmaceuticals (NASDAQ:RXRX) - Benzinga

Dec 10, 2024
pulisher
Dec 09, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 21.5% HigherShould You Buy? - MarketBeat

Dec 09, 2024
pulisher
Dec 09, 2024

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245 (NASDAQ:RXRX) - Seeking Alpha

Dec 09, 2024
pulisher
Dec 09, 2024

Charles Schwab Investment Management Inc. Has $12.79 Million Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

Dec 09, 2024
pulisher
Dec 08, 2024

Fmr LLC Buys 170,810 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat

Dec 08, 2024
pulisher
Dec 07, 2024

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Benjamin Edwards Inc. - MarketBeat

Dec 07, 2024
pulisher
Dec 06, 2024

Recursion Pharmaceuticals CEO sells $285,600 in stock By Investing.com - Investing.com Nigeria

Dec 06, 2024
pulisher
Dec 06, 2024

Recursion Pharmaceuticals CEO sells $285,600 in stock - Investing.com India

Dec 06, 2024
pulisher
Dec 06, 2024

RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 - MSN

Dec 06, 2024
pulisher
Dec 06, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.7%Time to Buy? - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

Stock Traders Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat

Dec 06, 2024
pulisher
Dec 05, 2024

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.9%Should You Sell? - MarketBeat

Dec 05, 2024
pulisher
Dec 05, 2024

The Future of Medicine: How AI Is Transforming Healthcare and Stock Markets - Baystreet.ca

Dec 05, 2024

Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Cap:     |  Volume (24h):